IT1404270B1 - Modulatori allosterici positivi di mglur5 per l'impiego come medicamento nel trattamento terapeutico della sindrome di phelan-mcdermid - Google Patents
Modulatori allosterici positivi di mglur5 per l'impiego come medicamento nel trattamento terapeutico della sindrome di phelan-mcdermidInfo
- Publication number
- IT1404270B1 IT1404270B1 ITTO2011A000169A ITTO20110169A IT1404270B1 IT 1404270 B1 IT1404270 B1 IT 1404270B1 IT TO2011A000169 A ITTO2011A000169 A IT TO2011A000169A IT TO20110169 A ITTO20110169 A IT TO20110169A IT 1404270 B1 IT1404270 B1 IT 1404270B1
- Authority
- IT
- Italy
- Prior art keywords
- allglass
- phelan
- mglur5
- modulators
- medication
- Prior art date
Links
- 101150087728 Grm5 gene Proteins 0.000 title 1
- 102100038357 Metabotropic glutamate receptor 5 Human genes 0.000 title 1
- 208000033180 Monosomy 22q13.3 Diseases 0.000 title 1
- 201000006880 Phelan-McDermid syndrome Diseases 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITTO2011A000169A IT1404270B1 (it) | 2011-02-28 | 2011-02-28 | Modulatori allosterici positivi di mglur5 per l'impiego come medicamento nel trattamento terapeutico della sindrome di phelan-mcdermid |
| PCT/IB2012/050894 WO2012117334A1 (en) | 2011-02-28 | 2012-02-27 | Mglur5 positive allosteric modulators for use in the treatment phelan-mcdermid syndrome |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITTO2011A000169A IT1404270B1 (it) | 2011-02-28 | 2011-02-28 | Modulatori allosterici positivi di mglur5 per l'impiego come medicamento nel trattamento terapeutico della sindrome di phelan-mcdermid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ITTO20110169A1 ITTO20110169A1 (it) | 2012-08-29 |
| IT1404270B1 true IT1404270B1 (it) | 2013-11-15 |
Family
ID=43976498
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ITTO2011A000169A IT1404270B1 (it) | 2011-02-28 | 2011-02-28 | Modulatori allosterici positivi di mglur5 per l'impiego come medicamento nel trattamento terapeutico della sindrome di phelan-mcdermid |
Country Status (2)
| Country | Link |
|---|---|
| IT (1) | IT1404270B1 (it) |
| WO (1) | WO2012117334A1 (it) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014210538A1 (en) * | 2013-06-28 | 2014-12-31 | The Regents Of The University Of California | Treating cognitive deficits associated with noonan syndrome |
| CA3084457A1 (en) * | 2017-10-27 | 2019-05-02 | Amo Pharma Ltd. | Methods of treating phelan mcdermid syndrome using farnesyl dibenzodiazepinones |
| CN113222975B (zh) * | 2021-05-31 | 2023-04-07 | 湖北工业大学 | 一种基于改进U-net的高精度视网膜血管分割方法 |
-
2011
- 2011-02-28 IT ITTO2011A000169A patent/IT1404270B1/it active
-
2012
- 2012-02-27 WO PCT/IB2012/050894 patent/WO2012117334A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| ITTO20110169A1 (it) | 2012-08-29 |
| WO2012117334A8 (en) | 2013-05-10 |
| WO2012117334A1 (en) | 2012-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL285843A (en) | Ibrutinib for use in the treatment of chronic graft versus host disease | |
| IL234023A0 (en) | New compositions for treating amyotrophic lateral sclerosis | |
| HRP20181378T1 (hr) | Postupci liječenja pedijatrijskih pacijenata deksmedetomidinom | |
| HUE039864T2 (hu) | Gyógyászati készítmények CFTR-közvetítette betegségek kezelésére | |
| IL231533B (en) | Fusion proteins for treating metabolic disorders | |
| PL2717692T3 (pl) | Kwasy tetrahydrokannabinol-11-owe do stosowania w leczeniu chorób zwłóknieniowych | |
| IL235512B (en) | Phenylbenzamide derivatives for use in treating diseases mediated by aquaporin | |
| IL229474B (en) | Cannabinoids for use in the treatment of neuropathic pain | |
| PL2582366T3 (pl) | Kombinacja farmaceutyczna do leczenia bólu | |
| HUE053565T2 (hu) | Adagolási rendek Pompe betegség kezelésére | |
| HUE054196T2 (hu) | Terápiás szerek nemkívánatos sejtproliferációhoz kapcsolódó betegségek kezelésére | |
| IL233313A0 (en) | Composition of novel carbohydrate drug for treatment of human diseases | |
| IL228030B (en) | Compounds for treating hyperuricemia and metabolic disorders associated with hyperuricemia | |
| IL229858B (en) | Polypeptides and uses thereof for tratment of autoimmune disorders and infection | |
| PL2613798T5 (pl) | Zastosowanie lizosomalnej kwaśnej lipazy do leczenia niedoboru lizosomalnej kwaśnej lipazy u pacjentów | |
| EP2850093A4 (en) | THERAPEUTIC IL-13 POLYPEPTIDES | |
| GB201511770D0 (en) | Novel pharmaceutical formulationsand their use in the treatment of periodontal disease | |
| IL234606B (en) | Novel methods and composition for treatment of disease | |
| IL227747A0 (en) | Combinations comprising macitentan for the treatment of glioblastoma multiforme | |
| EP2522360A4 (en) | VACCINE FOR TAUTOPATHY TREATMENT | |
| LT2872145T (lt) | Sujungti benzazepinai tureto sindromui gydyti | |
| ITRM20120530A1 (it) | Compounds for use in the treatment of parasitic diseases | |
| PL2904009T3 (pl) | Związki do leczenia blokady mielinizacji w chorobach związanych z ekspresją białka otoczki herv-w | |
| EP2861243A4 (en) | INTRANASAL ADMINISTRATION OF CELL PERMEABLES THERAPEUTICS FOR THE TREATMENT OF Oedemas | |
| IT1404270B1 (it) | Modulatori allosterici positivi di mglur5 per l'impiego come medicamento nel trattamento terapeutico della sindrome di phelan-mcdermid |